First Personal Financial Services boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 17.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,024 shares of the medical research company’s stock after buying an additional 453 shares during the period. First Personal Financial Services’ holdings in Amgen were worth $460,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock worth $2,030,789,000 after buying an additional 1,864,688 shares during the period. Geode Capital Management LLC boosted its position in Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock worth $964,334,000 after buying an additional 132,632 shares during the period. Nordea Investment Management AB boosted its position in Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock worth $870,171,000 after buying an additional 1,547,099 shares during the period. UBS Asset Management Americas Inc. boosted its position in Amgen by 5.9% in the second quarter. UBS Asset Management Americas Inc. now owns 3,930,676 shares of the medical research company’s stock worth $598,051,000 after buying an additional 218,029 shares during the period. Finally, LSV Asset Management boosted its position in Amgen by 0.3% in the second quarter. LSV Asset Management now owns 3,271,393 shares of the medical research company’s stock worth $497,742,000 after buying an additional 9,605 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 174.80 on Friday. The company has a 50-day moving average price of $172.09 and a 200 day moving average price of $160.08. Amgen Inc. has a one year low of $130.09 and a one year high of $176.85. The company has a market capitalization of $130.81 billion, a PE ratio of 17.89 and a beta of 0.87.
Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same quarter last year, the company earned $2.57 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year. Equities analysts anticipate that Amgen Inc. will post $11.36 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were issued a $1.00 dividend. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 annualized dividend and a dividend yield of 2.29%. Amgen’s payout ratio is currently 40.90%.
A number of equities research analysts have recently weighed in on the company. Jefferies Group lifted their target price on Amgen from $187.00 to $198.00 and gave the stock a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price for the company in a report on Wednesday, June 29th. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price for the company in a report on Monday, June 13th. Leerink Swann reissued a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Finally, Argus reissued a “buy” rating and set a $195.00 target price (up previously from $185.00) on shares of Amgen in a report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $184.56.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.